Welcome to our dedicated page for CLRBW news (Ticker: CLRBW), a resource for investors and traders seeking the latest updates and insights on CLRBW stock.
The CLRBW news page tracks developments related to Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical and radiopharmaceutical company whose common stock trades under the symbol CLRB and whose warrants trade as CLRBW. Company press releases describe a focus on the discovery and development of proprietary drugs for the treatment of cancer, using a Phospholipid Drug Conjugate (PDC) delivery platform and phospholipid ether technology to create targeted radiotherapeutics.
News linked to CLRBW typically covers Cellectar’s clinical and regulatory progress. Recent announcements highlight plans to submit a Conditional Marketing Authorization application in Europe for iopofosine I 131 in Waldenstrom’s macroglobulinemia, guidance from the European Medicines Agency’s Scientific Advice Working Party, and multiple U.S. Food and Drug Administration designations such as Breakthrough Therapy, Orphan Drug, Rare Pediatric Drug and Fast Track for various indications. Updates also describe interim data from the CLOVER-2 Phase 1b study in pediatric high-grade gliomas and Phase 2b data in hematologic malignancies.
Investors following CLRBW-related news can also review releases on Cellectar’s broader pipeline, including CLR 121125 (CLR 125), an iodine-125 Auger-emitting program for solid tumors such as triple-negative breast, lung and colorectal cancers, and CLR 121225 (CLR 225), an actinium-225 based program aimed at pancreatic and other solid tumors. Additional items include supply agreements for key radioisotopes, collaborations with contract research organizations, and financing transactions involving warrants and common stock that support ongoing clinical development.
By monitoring the CLRBW news feed, readers can see how Cellectar characterizes its scientific platform, clinical trial milestones, regulatory interactions and capital-raising activities, all of which provide context for the underlying equity to which the warrants are tied.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has scheduled its third quarter 2024 financial results announcement and corporate update for November 18, 2024, at 8:30 a.m. ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 with conference ID 80659, and a webcast will be available. A replay of the call will be accessible through the company's investor relations website.